News | December 07, 2021
Study shows Glaxo-Vir drug works against Omicron mutations
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Subscribe To Our Newsletter & Stay Updated
